Recent Updates
Recently added Catalysts

Iambic Therapeutics, Inc.

IAMFDA catalysts, PDUFA dates & pipeline intelligence
$14.22
▲ +2.37 · +20%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IAM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
489.27 K
Value Traded
6.74 M
Short % Float
-

Cash Data

Unlock IAM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
674.04 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
47.40 M
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data presentation
IAM217 (KIF18A)
triple-negative breast cancer, ovarian cancer, other solid tumors with chromosomal instability
Pre-clinicalSmall MoleculesOncology
Unlock every IAM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IAM Catalyst Timeline

Dated clinical, regulatory and corporate events for Iambic Therapeutics, Inc.

Unlock the full IAM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IAM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all IAM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the IAM pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IAM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every IAM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IAM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full IAM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in IAM for Q3 2026.
Unlock every fund holding IAM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IAM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IAM ownership
Insider and institutional ownership, quarter by quarter.

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IAM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IAM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IAM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IAM ranks across every disease it competes in

Competitive Position is a premium feature
See how IAM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IAM News

-IAM
Nov 16, 2026
IAMGeneral
▲ +20%today

Iambic Provides Business Updates and Third Quarter 2026 Financial Results

Iambic reported strong third quarter results, highlighting the launch of Enchant v3 and collaborations with Bayer and AbbVie. The company achieved a milestone payment from Takeda and presented promising data for IAM1363 at ESMO 2026. With a cash position of approximately $455 million, Iambic is well-positioned for future developments.

Read more →
-IAM
Nov 9, 2026
IAMConferences/Events

Iambic to participate in Jefferies Global Healthcare Conference

Iambic's CEO, Tom Miller, will participate in the Jefferies Global Healthcare Conference from November 16-19, 2026. He will join a panel discussing AI in drug discovery on November 18. The conference is a significant event in Europe for healthcare leaders. Iambic aims to enhance drug development through its AI-driven platform.

Read more →
-IAM
Oct 26, 2026
IAMPhases

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Iambic Therapeutics presented updated clinical data for IAM1363 at ESMO 2026, showing durable responses and a favorable tolerability profile in heavily pretreated patients with HER2-driven cancers. The Phase 1/1b study demonstrated low rates of serious adverse events and notable intracranial responses. Over half of the participants treated with IAM1363 remain on study, indicating promising efficacy.

Read more →
-IAM
Oct 14, 2026
IAMGeneral

Iambic Announces Pricing of Initial Public Offering

Iambic Therapeutics announced the pricing of its initial public offering at $16.00 per share, aiming to raise $150.0 million. The IPO includes 9,375,000 shares, with an additional option for underwriters to purchase more. Trading is set to commence on October 15, 2026, on the Nasdaq under the ticker 'IAM'.

Read more →
-IAM
Oct 5, 2026
IAMFDA Updates

Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

Iambic Therapeutics has submitted an IND application for IAM217, a KIF18A inhibitor, to the FDA for a Phase 1/2 trial. The drug demonstrated about 90% tumor regression in preclinical models and targets triple-negative breast cancer and other solid tumors. This marks Iambic's second candidate entering clinical trials, following IAM1363.

Read more →
-IAM
Sep 21, 2026
IAMGeneral

Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

Iambic launched Enchant v3, an advanced multimodal transformer model designed to enhance drug discovery and development. With 41 billion parameters and trained on diverse biomedical data, it aims to optimize decision-making processes. The new model builds on previous versions, demonstrating improved predictive capabilities and supporting the company's mission to develop better medicines.

Read more →
-IAM
Jun 22, 2026
IAMGeneral

Bayer and Iambic collaborate to advance drug discovery with AI

Bayer and Iambic Therapeutics announced a collaboration to enhance drug discovery using Iambic's AI platform. This partnership focuses on small molecule discovery and aims to identify novel drug entry points. By leveraging AI, the collaboration seeks to accelerate drug development timelines and strengthen Bayer's research portfolio.

Read more →
-IAM
May 19, 2026
IAMGeneral

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic has been recognized as a CNBC Disruptor 50 for the second consecutive year, highlighting its innovative approach in drug discovery. The company has formed significant partnerships, including a $1.7 billion deal with Takeda. Iambic's AI-driven platform has shown promising results, including rapid clinical advancements for its drug candidate IAM1363.

Read more →
-IAM
May 11, 2026
IAMConferences/Events

Iambic to participate in upcoming investor conferences

Iambic announced its participation in several upcoming investor conferences, including the Bank of America Healthcare Conference and the Jefferies Global Healthcare Conference. Key executives, including CEO Tom Miller and CFO Michael Secora, will engage with investors and present the company's advancements. Iambic focuses on developing novel medicines through its AI-driven platform.

Read more →

About Iambic Therapeutics, Inc.

BIOPHARMAWATCH ELITE
Trade the next IAM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime